Latest news
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 12:00:00 GMTDatroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 06:30:00 GMTDatroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy - AstraZenecaAstraZeneca · Fri, 31 Jul 2026 02:00:00 GMTLeading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 07:00:00 GMTUse of Oral Targeted Anticancer Drugs Grows, Evidence of Survival Benefit Often Lacking - cancertherapyadvisor.comcancertherapyadvisor.com · Wed, 29 Jul 2026 04:00:00 GMTSonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers - AstraZenecaAstraZeneca · Mon, 27 Jul 2026 07:00:00 GMTSonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer - OncLiveOncLive · Mon, 27 Jul 2026 07:00:00 GMTAstraZeneca Says Phase 3 Sone-Ve Trial Shows Overall Survival Benefit in Advanced Gastric Cancer - marketscreener.commarketscreener.com · Mon, 27 Jul 2026 07:00:00 GMT